<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00766363</url>
  </required_header>
  <id_info>
    <org_study_id>EVP-6124-007</org_study_id>
    <nct_id>NCT00766363</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FORUM Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INC Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>FORUM Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to determine the safety, tolerability, and pharmacokinetics
      (PK) of three different doses of an investigational medication, EVP-6124, in individuals with
      mild to moderate Alzheimer's disease who are also taking an Alzheimer's medication (AChEI
      [acetylcholinesterase inhibitor]: either donepezil or rivastigmine). In addition, PK of AChEI
      medications will be assessed. Cognitive function will be evaluated on an exploratory basis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, Phase 1b safety study of three dose
      levels of EVP-6124 in subjects with mild or moderate Alzheimer's disease and who are taking
      an AChEI medication (donepezil or rivastigmine).

      Study drug will be supplied as capsules and will be orally administered once daily for a
      total of 28 days. Eligible subjects will be admitted to an inpatient study unit on Day -2
      (two days before the first dose of study drug is administered) and will remain confined to
      the inpatient study unit for a total of five days. Starting on Day 4, subjects will continue
      the study in the outpatient setting, with study visits on Days 7, 14, 21, and 28. Safety
      assessments, PK sampling, and cognitive testing will be performed inpatient and at each study
      visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of Multiple Doses of EVP-6124 or Placebo in Subjects With Alzheimer's Disease</measure>
    <time_frame>Pre-treatment (Day -2) [or screening for physical examination] to Day 28 [or Day 35, for AEs only]</time_frame>
    <description>All adverse experiences spontaneously reported by subject and/or observed by investigator and repeated clinical evaluation of physical examinations, vital signs, 12-lead ECG (electrocardiogram), ambulatory ECG, and laboratory tests (hematology/blood chemistry/urinalysis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EVP-6124 PK Data Following the First Dose of EVP-6124 - Maximum Concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>EVP-6124 PK data; Maximum Concentration (Cmax); i.e, highest concentration of drug in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EVP-6124 PK Data Following the First Dose of EVP-6124 - Time to Maximum Concentration (Tmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>EVP-6124 PK data; Time to Maximum Concentration (Tmax); i.e, amount of time required to reach highest concentration of drug in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EVP-6124 PK Data Following the First Dose of EVP-6124 - Area Under the Curve (AUC[0-24 h])</measure>
    <time_frame>24 hours</time_frame>
    <description>EVP-6124 PK data; Area Under the Curve (AUC[0-24 h]); i.e, area under the concentration-time plot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donepezil PK Data Following the First Dose of EVP-6124 - Maximum Concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>Donepezil PK data; Maximum Concentration (Cmax); i.e, highest concentration of donepezil (parent compound only) in plasma after dosing with EVP-6124</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donepezil PK Data Following the First Dose of EVP-6124 - Time to Maximum Concentration (Tmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>Donepezil PK data; Time to Maximum Concentration (Tmax); i.e, amount of time required to reach highest concentration of donepezil (parent compound only) in plasma after dosing with EVP-6124</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donepezil PK Data Following the First Dose of EVP-6124 - Area Under the Curve (AUC[0-24 h])</measure>
    <time_frame>24 hours</time_frame>
    <description>Donepezil PK data; Area Under the Curve (AUC[0-24 h]); i.e, area under the concentration-time plot for donepezil (parent compound only) after dosing with EVP-6124</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rivastigmine PK Data Following the First Dose of EVP-6124 - Maximum Concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>Rivastigmine PK data; Maximum Concentration (Cmax); i.e, highest concentration of rivastigmine in plasma after dosing with EVP-6124</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rivastigmine PK Data Following the First Dose of EVP-6124 - Time to Maximum Concentration (Tmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>Rivastigmine PK data; Time to Maximum Concentration (Tmax); i.e, amount of time required to reach highest concentration of rivastigmine in plasma after dosing with EVP-6124</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rivastigmine PK Data Following the First Dose of EVP-6124 - Area Under the Curve (AUC[0-24 h])</measure>
    <time_frame>24 hours</time_frame>
    <description>Rivastigmine PK data; Area Under the Curve (AUC[0-24 h]); i.e, area under the concentration-time plot for rivastigmine after dosing with EVP-6124</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Central Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>EVP-6124 (0.1 mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EVP-6124 (0.3 mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EVP-6124 (1.0 mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EVP-6124 (0.1 mg/day)</intervention_name>
    <description>EVP-6124 was administered as one 0.1 mg capsule per day for 28 days.</description>
    <arm_group_label>EVP-6124 (0.1 mg/day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EVP-6124 (0.3 mg/day)</intervention_name>
    <description>EVP-6124 was administered as one 0.3 mg capsule every day for 28 days.</description>
    <arm_group_label>EVP-6124 (0.3 mg/day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EVP-6124 (1.0 mg/day)</intervention_name>
    <description>EVP-6124 was administered as one 1.0 mg capsule every day for 28 days.</description>
    <arm_group_label>EVP-6124 (1.0 mg/day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Matching placebo was administered as one capsule per day for 28 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Concomitant therapy with donepezil at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.</description>
    <arm_group_label>EVP-6124 (0.1 mg/day)</arm_group_label>
    <arm_group_label>EVP-6124 (0.3 mg/day)</arm_group_label>
    <arm_group_label>EVP-6124 (1.0 mg/day)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine</intervention_name>
    <description>Concomitant therapy with rivastigmine at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.</description>
    <arm_group_label>EVP-6124 (0.1 mg/day)</arm_group_label>
    <arm_group_label>EVP-6124 (0.3 mg/day)</arm_group_label>
    <arm_group_label>EVP-6124 (1.0 mg/day)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and post-menopausal or surgically sterile female pts

          -  50-90 yrs old, who meet clinical criteria for probable Alzheimer's disease
             (Mini-Mental State Examination of 18-26; Hachinski Ischemic Score ≤4)

          -  must be taking donepezil or rivastigmine for at least 3 mos.

        Exclusion Criteria:

          -  Unstable medical condition that is clinically significant in the judgment of the
             investigator; major organ system dysfunction

          -  Untreated hypothyroidism

          -  Insufficiently controlled diabetes mellitus

          -  Diagnosis of major depression requiring antidepressant medications within the last 5
             years

          -  Stroke within 6 months before screening, or concomitant with onset of dementia

          -  Certain concomitant medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R. Hassmann, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beth Safirstein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Clinical</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Thein, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pacific Research Network, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Apter, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Global Medical Institutes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Research Network, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Research</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Medical Institutes, LLC</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2008</study_first_submitted>
  <study_first_submitted_qc>October 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2008</study_first_posted>
  <results_first_submitted>June 16, 2011</results_first_submitted>
  <results_first_submitted_qc>June 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2011</results_first_posted>
  <last_update_submitted>April 18, 2012</last_update_submitted>
  <last_update_submitted_qc>April 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Rivastigmine</mesh_term>
    <mesh_term>Nicotinic Agonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period was from September 2008 to February 2009 at 4 study centers in the US (CA, FL, and 2 in NJ).</recruitment_details>
      <pre_assignment_details>61 subjects were screened and 49 subjects were enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>EVP-6124 (0.1 mg/Day)</title>
          <description>1 capsule per day for 28 days.</description>
        </group>
        <group group_id="P2">
          <title>EVP-6124 (0.3 mg/Day)</title>
          <description>1 capsule per day for 28 days.</description>
        </group>
        <group group_id="P3">
          <title>EVP-6124 (1.0 mg/Day)</title>
          <description>1 capsule per day for 28 days.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>1 capsule per day for 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12">Number randomized.</participants>
                <participants group_id="P4" count="12">Number randomized.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>SAFETY POPULATION</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="11">Decreased by one subject who took placebo instead due to treatment assignment error.</participants>
                <participants group_id="P4" count="13">Increased by one subject who took placebo due to treatment assignment error.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>PK POPULATION</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event Prior to Randomization</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EVP-6124 (0.1 mg/Day)</title>
          <description>1 capsule per day for 28 days.</description>
        </group>
        <group group_id="B2">
          <title>EVP-6124 (0.3 mg/Day)</title>
          <description>1 capsule per day for 28 days.</description>
        </group>
        <group group_id="B3">
          <title>EVP-6124 (1.0 mg/Day)</title>
          <description>1 capsule per day for 28 days.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>1 capsule per day for 28 days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.6" spread="8.5"/>
                    <measurement group_id="B2" value="68.3" spread="11.1"/>
                    <measurement group_id="B3" value="70.2" spread="12.3"/>
                    <measurement group_id="B4" value="72.0" spread="10.5"/>
                    <measurement group_id="B5" value="69.8" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Multiple Doses of EVP-6124 or Placebo in Subjects With Alzheimer’s Disease</title>
        <description>All adverse experiences spontaneously reported by subject and/or observed by investigator and repeated clinical evaluation of physical examinations, vital signs, 12-lead ECG (electrocardiogram), ambulatory ECG, and laboratory tests (hematology/blood chemistry/urinalysis)</description>
        <time_frame>Pre-treatment (Day -2) [or screening for physical examination] to Day 28 [or Day 35, for AEs only]</time_frame>
        <population>Safety Population: All randomized subjects who ingested at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (0.1 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Multiple Doses of EVP-6124 or Placebo in Subjects With Alzheimer’s Disease</title>
          <description>All adverse experiences spontaneously reported by subject and/or observed by investigator and repeated clinical evaluation of physical examinations, vital signs, 12-lead ECG (electrocardiogram), ambulatory ECG, and laboratory tests (hematology/blood chemistry/urinalysis)</description>
          <population>Safety Population: All randomized subjects who ingested at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Adverse Events Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EVP-6124 PK Data Following the First Dose of EVP-6124 – Maximum Concentration (Cmax)</title>
        <description>EVP-6124 PK data; Maximum Concentration (Cmax); i.e, highest concentration of drug in plasma</description>
        <time_frame>24 hours</time_frame>
        <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (0.1 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>EVP-6124 PK Data Following the First Dose of EVP-6124 – Maximum Concentration (Cmax)</title>
          <description>EVP-6124 PK data; Maximum Concentration (Cmax); i.e, highest concentration of drug in plasma</description>
          <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0715" spread="0.0121"/>
                    <measurement group_id="O2" value="0.1911" spread="0.0740"/>
                    <measurement group_id="O3" value="0.6122" spread="0.1235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EVP-6124 PK Data Following the First Dose of EVP-6124 – Time to Maximum Concentration (Tmax)</title>
        <description>EVP-6124 PK data; Time to Maximum Concentration (Tmax); i.e, amount of time required to reach highest concentration of drug in plasma</description>
        <time_frame>24 hours</time_frame>
        <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (0.1 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>EVP-6124 PK Data Following the First Dose of EVP-6124 – Time to Maximum Concentration (Tmax)</title>
          <description>EVP-6124 PK data; Time to Maximum Concentration (Tmax); i.e, amount of time required to reach highest concentration of drug in plasma</description>
          <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.70" spread="3.31"/>
                    <measurement group_id="O2" value="7.94" spread="3.61"/>
                    <measurement group_id="O3" value="10.72" spread="6.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EVP-6124 PK Data Following the First Dose of EVP-6124 – Area Under the Curve (AUC[0-24 h])</title>
        <description>EVP-6124 PK data; Area Under the Curve (AUC[0-24 h]); i.e, area under the concentration-time plot</description>
        <time_frame>24 hours</time_frame>
        <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (0.1 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>EVP-6124 PK Data Following the First Dose of EVP-6124 – Area Under the Curve (AUC[0-24 h])</title>
          <description>EVP-6124 PK data; Area Under the Curve (AUC[0-24 h]); i.e, area under the concentration-time plot</description>
          <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.23"/>
                    <measurement group_id="O2" value="3.89" spread="0.84"/>
                    <measurement group_id="O3" value="11.44" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donepezil PK Data Following the First Dose of EVP-6124 – Maximum Concentration (Cmax)</title>
        <description>Donepezil PK data; Maximum Concentration (Cmax); i.e, highest concentration of donepezil (parent compound only) in plasma after dosing with EVP-6124</description>
        <time_frame>24 hours</time_frame>
        <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (0.1 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Donepezil PK Data Following the First Dose of EVP-6124 – Maximum Concentration (Cmax)</title>
          <description>Donepezil PK data; Maximum Concentration (Cmax); i.e, highest concentration of donepezil (parent compound only) in plasma after dosing with EVP-6124</description>
          <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" spread="15.8"/>
                    <measurement group_id="O2" value="24.7" spread="19.8"/>
                    <measurement group_id="O3" value="39.2" spread="26.7"/>
                    <measurement group_id="O4" value="41.9" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donepezil PK Data Following the First Dose of EVP-6124 – Time to Maximum Concentration (Tmax)</title>
        <description>Donepezil PK data; Time to Maximum Concentration (Tmax); i.e, amount of time required to reach highest concentration of donepezil (parent compound only) in plasma after dosing with EVP-6124</description>
        <time_frame>24 hours</time_frame>
        <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (0.1 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Donepezil PK Data Following the First Dose of EVP-6124 – Time to Maximum Concentration (Tmax)</title>
          <description>Donepezil PK data; Time to Maximum Concentration (Tmax); i.e, amount of time required to reach highest concentration of donepezil (parent compound only) in plasma after dosing with EVP-6124</description>
          <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="2.65"/>
                    <measurement group_id="O2" value="1.85" spread="2.15"/>
                    <measurement group_id="O3" value="3.31" spread="3.01"/>
                    <measurement group_id="O4" value="3.56" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donepezil PK Data Following the First Dose of EVP-6124 – Area Under the Curve (AUC[0-24 h])</title>
        <description>Donepezil PK data; Area Under the Curve (AUC[0-24 h]); i.e, area under the concentration-time plot for donepezil (parent compound only) after dosing with EVP-6124</description>
        <time_frame>24 hours</time_frame>
        <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (0.1 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Donepezil PK Data Following the First Dose of EVP-6124 – Area Under the Curve (AUC[0-24 h])</title>
          <description>Donepezil PK data; Area Under the Curve (AUC[0-24 h]); i.e, area under the concentration-time plot for donepezil (parent compound only) after dosing with EVP-6124</description>
          <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299" spread="179"/>
                    <measurement group_id="O2" value="240" spread="194"/>
                    <measurement group_id="O3" value="345" spread="225"/>
                    <measurement group_id="O4" value="427" spread="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rivastigmine PK Data Following the First Dose of EVP-6124 - Maximum Concentration (Cmax)</title>
        <description>Rivastigmine PK data; Maximum Concentration (Cmax); i.e, highest concentration of rivastigmine in plasma after dosing with EVP-6124</description>
        <time_frame>24 hours</time_frame>
        <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters. Only 4 subjects took rivastigmine concomitantly.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (0.1 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Rivastigmine PK Data Following the First Dose of EVP-6124 - Maximum Concentration (Cmax)</title>
          <description>Rivastigmine PK data; Maximum Concentration (Cmax); i.e, highest concentration of rivastigmine in plasma after dosing with EVP-6124</description>
          <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters. Only 4 subjects took rivastigmine concomitantly.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.35" spread="5.16"/>
                    <measurement group_id="O2" value="3.51" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rivastigmine PK Data Following the First Dose of EVP-6124 - Time to Maximum Concentration (Tmax)</title>
        <description>Rivastigmine PK data; Time to Maximum Concentration (Tmax); i.e, amount of time required to reach highest concentration of rivastigmine in plasma after dosing with EVP-6124</description>
        <time_frame>24 hours</time_frame>
        <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters. Only 4 subjects took rivastigmine concomitantly.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (0.1 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Rivastigmine PK Data Following the First Dose of EVP-6124 - Time to Maximum Concentration (Tmax)</title>
          <description>Rivastigmine PK data; Time to Maximum Concentration (Tmax); i.e, amount of time required to reach highest concentration of rivastigmine in plasma after dosing with EVP-6124</description>
          <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters. Only 4 subjects took rivastigmine concomitantly.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.02"/>
                    <measurement group_id="O2" value="12.12" spread="15.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rivastigmine PK Data Following the First Dose of EVP-6124 - Area Under the Curve (AUC[0-24 h])</title>
        <description>Rivastigmine PK data; Area Under the Curve (AUC[0-24 h]); i.e, area under the concentration-time plot for rivastigmine after dosing with EVP-6124</description>
        <time_frame>24 hours</time_frame>
        <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters. Only 4 subjects took rivastigmine concomitantly.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (0.1 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>1 capsule per day for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Rivastigmine PK Data Following the First Dose of EVP-6124 - Area Under the Curve (AUC[0-24 h])</title>
          <description>Rivastigmine PK data; Area Under the Curve (AUC[0-24 h]); i.e, area under the concentration-time plot for rivastigmine after dosing with EVP-6124</description>
          <population>PK Population: All safety population subjects who had sufficient plasma concentration data to facilitate calculation of PK parameters. Only 4 subjects took rivastigmine concomitantly.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.55" spread="85.52"/>
                    <measurement group_id="O2" value="54.60" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from pre-treatment (Day -2) to 7 days after the last dose of study drug (Day 35).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>EVP-6124 (0.1 mg/Day)</title>
          <description>1 capsule per day for 28 days.</description>
        </group>
        <group group_id="E2">
          <title>EVP-6124 (0.3 mg/Day)</title>
          <description>1 capsule per day for 28 days.</description>
        </group>
        <group group_id="E3">
          <title>EVP-6124 (1.0 mg/Day)</title>
          <description>1 capsule per day for 28 days.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>1 capsule per day for 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted for review. At the sponsor’s request, the PI will delete confidential information other than trial data and will delay publication or disclosure for up to 90 days to allow patent filings. The PI agrees that the first publication shall be a joint publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maria Gawryl, Ph.D., Vice President, Regulatory Affairs &amp; Drug Development</name_or_title>
      <organization>EnVivo Pharmaceuticals, Inc.</organization>
      <phone>617-225-4264</phone>
      <email>mgawryl@envivopharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

